Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Uni-Bio and Beijing Sun-Novo to Co-Develop Diabetes Treatments

publication date: Dec 2, 2016
Uni-Bio Science of Hong Kong signed an agreement with Beijing Sun-Novo Pharma to co-develop multiple oral small molecule treatments for diabetes in China. Initially, the two companies will focus on developing acarbose-class tablets to treat type 2 diabetes, and the collaboration will continue to develop a portfolio of diabetes-aimed products. Beijing Sun-Novo will complete the chemistry, manufacturing and control processes along with the bioequivalence study of acarbose. Uni-Bio will apply for drug licenses from the CFDA and commercialize the product upon approval. More details....

Stock Symbol: (HK: 690)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital